Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

S'inscrire

QNRX Quoin Pharmaceuticals Ltd

0,30

-0,0098 (-3,16%)

Dernière mise à jour : 16:09:30

Retardé de 15 minutes

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Quoin Pharmaceuticals (NASDAQ:QNRX)
Graphique Historique de l'Action
De Fév 2025 à Mar 2025

Plus de graphiques de la Bourse Quoin Pharmaceuticals

Quoin Pharmaceuticals (NASDAQ:QNRX)
Graphique Historique de l'Action
De Mar 2024 à Mar 2025

Plus de graphiques de la Bourse Quoin Pharmaceuticals

Actualités Quoin Pharmaceuticals Ltd

Quoin Pharmaceuticals to Announce Fourth Quarter and Full-Year 2024 Financial Results on Thursday, March 13, 2025
Jeudi 6 Mars 2025 ( il y a 4 jours) • GlobeNewswire Inc.

Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications
Mardi 4 Mars 2025 ( il y a 6 jours) • GlobeNewswire Inc.

Form 8-K - Current report
Jeudi 27 Février 2025 ( il y a 2 semaines) • Edgar (US Regulatory)

Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study
Jeudi 27 Février 2025 ( il y a 2 semaines) • GlobeNewswire Inc.

Quoin Pharmaceuticals Launches First Episode of “NETHERTON NOW” Video Series to Raise Awareness for Netherton Syndrome
Mardi 25 Février 2025 ( il y a 2 semaines) • GlobeNewswire Inc.

Form 8-K - Current report
Mardi 4 Février 2025 ( il y a 1 mois) • Edgar (US Regulatory)

Quoin Pharmaceuticals Launches ‘NETHERTON NOW’ Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure
Mardi 4 Février 2025 ( il y a 1 mois) • GlobeNewswire Inc.

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
Mardi 28 Janvier 2025 ( il y a 1 mois) • Edgar (US Regulatory)

Form 8-K - Current report
Jeudi 23 Janvier 2025 ( il y a 2 mois) • Edgar (US Regulatory)

Quoin Pharmaceuticals Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome
Jeudi 23 Janvier 2025 ( il y a 2 mois) • GlobeNewswire Inc.

Form 8-K - Current report
Jeudi 16 Janvier 2025 ( il y a 2 mois) • Edgar (US Regulatory)

Quoin Pharmaceuticals Announces Further Positive Clinical Data from Ongoing Pediatric Netherton Syndrome Study
Mardi 14 Janvier 2025 ( il y a 2 mois) • GlobeNewswire Inc.

Plus d'articles sur Quoin Pharmaceuticals Ltd

Vontobel Financial Produ...

HSBC MSCI CHINA ETF

BNP Paribas Issuance

Vontobel Financial Produ...

Vontobel Financial Produ...

Vontobel Financial Produ...

Vontobel Financial Produ...

Vontobel Financial Produ...

Vontobel Financial Produ...

Exchange Trading Funds

Exchange Traded

Exchange Traded

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales